Adverse events associated with mirabegron 50mg versus placebo: A systematic review and meta-analysis
Authors:
- 1 September 2021
- journal article
- review article
- Published by Elsevier in Progrès en Urologie
- Vol. 31 (11) , 627-633
Abstract
No abstract availableKeywords
Funding Information
- Department of Education of Liaoning Province
This publication has 23 references indexed in Scilit:
- A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive BladderUrology, 2013
- Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive BladderJournal of Urology, 2013
- A phase II dose-ranging study of mirabegron in patients with overactive bladderInternational Urogynecology Journal, 2013
- Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 TrialEuropean Urology, 2013
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Update on the management of acute pharyngitis in childrenItalian Journal of Pediatrics, 2011
- Patient‐reported reasons for discontinuing overactive bladder medicationBJU International, 2010
- The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTSBJU International, 2009
- Effect of (R)-2-(2-Aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} Acetanilide (YM178), a Novel Selective β3-Adrenoceptor Agonist, on Bladder FunctionThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladderBritish Journal of Pharmacology, 2006